NEW YORK, NY / ACCESSWIRE / March 21, 2017 / Biotech firms are speculative in many ways, especially when investing in lower priced stocks. FDA trials can take a nose dive, resulting in the stock price following in its wake. Some biotech stocks fail spectacularly, while when a company gets final approval from the FDA of a drug or technology, the rise in price can be equally spectacular for investors. Below are two stocks that are clearly on the mind of their investors today.

RDI Initiates
Coverage:

Esperion Therapeutics
Inc. https://ub.rdinvesting.com/news/?ticker=ESPR

Bellerophon
Therapeutics Inc. https://ub.rdinvesting.com/news/?ticker=BLPH

When do you know when you have bought exactly the right stock at the right time? When you were an investor in Esperion Therapeutics between March 17th and March 20th of this year. The stock’s opening price on Friday was $21.29. Its close on Monday was $41.22 a share. That tallies close to a 100 percent increase in the stock price in just two trading session. The stock shoot up 74 percent on company’s Monday press release of FDA confirmation of regulatory pathway to approval for its drug for LDl-C. In short, the company passed the Phase 3 FDA trial and can now globally begin to market and sell its cholesterol lowering drug. Earlier in the last week, Esperion was sliding down, possibly because of market concerns about pricing power of its upcoming drug to Amgen’s next generation drug “Repatha”. As the relatively weaker data of success rate and effectiveness of “Repatha” were out on Friday, Esperion started climbing up, and then came Monday’s press release: “Global Pivotal Phase 3 Program Design Can Support Approval for an LDL-C Lowering Indication” and then the news of investment rating upgrade from Credit Suisse to “neutral” from “underperform” subsequently on the same day. There is more to the press release, but the real news was that the stock price has doubled, and justified the investment.

Access RDI’s Esperion Therapeutics Research Report at: https://ub.rdinvesting.com/news/?ticker=ESPR

Investors in Bellerophon Therapeutics were a bit puzzled by the drop in stock price of the company on Friday, March 17th, as there was no news that warranted such a price drop. Likewise, investors today were talking about what triggered the stock’s drop in price by 45 cents a share on Friday afternoon’s close, only to find it recovered to end up 36 cents a share at $1.39 by the end of Monday’s trading day. Some investors remained puzzled by the price swing given the lack of any meaningful news from the company. Others posited it was an intentional manipulation of the stock price to buy more on Monday morning given the size of the company and by 10 a.m. the stock hit its daily high of $1.57. While the company’s INOPulse program for treatment of pulmonary arterial hypertension is going through Phase 3 right now, it has reported a loss of $0.37 a share for fourth quarter of 2016, significantly lower than loss of $0.83 reported in the same quarter prior year but higher than consensus estimate of loss of $0.21.

Access RDI’s Bellerophon Therapeutics Research Report at:
https://ub.rdinvesting.com/news/?ticker=BLPH

Our Actionable Research on Esperion Therapeutics Inc. (NASDAQ: ESPR) and Bellerophon Therapeutics Inc. (NASDAQ: BLPH) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information, please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 457810

NEW YORK, NY / ACCESSWIRE / March 21, 2017 / The current word from market observers is that the biotech sector may have new life breathed into it by a Republican led Congress and the new administration. New reforms regarding the holding of significant cash reserves by major pharmaceutical companies may allow that cash back into the company’s coffers, opening the door for increased acquisition activity in the sector. Also, there may be possible new FDA regulations regarding the expedition in the approval process of new drugs, allowing more new drugs, and profits, into the market.

RDI Initiates
Coverage:

Omeros Corporation https://ub.rdinvesting.com/news/?ticker=OMER

Keryx
Biopharmaceuticals https://ub.rdinvesting.com/news/?ticker=KERX

Omerus spiked up $1.54 from Friday’s close to end Monday at a price of $11.75 a share. The rise in price was questioned by some investors who noted the significant amount of insider trading of selling in the 4th quarter of 2016. The company develops and seeks to commercialize therapies that target inflammation, coagulopathies, and disorders of the central nervous system. The stock is up almost 18.5 percent for the year-to-date, and its lead candidate therapy, OMS721, is said to have some promise as the Phase-2 clinical trial of the drug was heralded as a success. Omeros has reported a loss of $66.75 million or $1.65 a share for the year of 2016, as against loss of $75.1 million or $2.00 a share reported in the year 2015. While revenue increased significantly to $41.6 million in the year 2016 up from $13.5 million of reported revenue in 2015, the company had $45.3 million of Cash, cash equivalents and short term investments as on December 31, 2016.

Access RDI’s Omeros Corporation Research Report at: https://ub.rdinvesting.com/news/?ticker=OMER

If you are an investor in a biotech company, and one of its drugs is approved to be placed on the formulary of one of the largest Part D Medicare Plans sponsors, you can start to give yourself credit for such excellent investing judgment. Such is the case for Keryx, whose stock shot up 46 cents to close at $6.29 per share on Monday. The drug, Auryxia(R), has been approved for immediate use and is used in the treatment for people for the control of serum phosphorus levels who are on end-stage type of renal disease. Keryx, with its recent sNDA submission on March 8th, is seeking to expand to include the treatment of iron deficiency anemia (IDA) in patients with non-dialysis dependent chronic kidney disease (NDD-CKD).

Access RDI’s Keryx Biopharmaceuticals Research Report at:
https://ub.rdinvesting.com/news/?ticker=KERX

Our Actionable Research on Omeros Corporation (NASDAQ: OMER) and Keryx Biopharmaceuticals (NASDAQ: KERX) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information, please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 457816

In Major Victory Federal Judge Denies J&J Motion to Dismiss, Rules DECN May Allege the Critical “Doctrine of Equivalents” in Nevada Federal Court

LOS ANGELES, CA / ACCESSWIRE / March 21, 2017 / Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator, and the exclusive worldwide sales, service, and regulatory processes agent for GenStrip™ 50 and the GenUltimate!™ glucose test strips, both designed to work with the market leading Johnson & Johnson’s (“J&J”) LifeScan OneTouch Ultra family of glucose testing meters, and the in-development GenSure!™ and GenChoice!™ glucose test strips targeted to the U.S. and/or developing world markets, today announces the recent legal victory in its prosecution campaign against J&J/Lifescan for its flagrant violation of the company’s US patents 6,153,069 and 6,413, 411.

Decision IT Corp. and PharmaTech Solutions, Inc., subsidiaries of Decision Diagnostics Corp., filed a lawsuit on March 14, 2016 in the United States District Court, District of Nevada, in Las Vegas, NV. The DECN companies named Johnson & Johnson and its divisions, Lifescan, Inc. and Lifescan Scotland Ltd., as having willfully infringed against two separate patents owned and/or practiced by the company’s subsidiaries. Predictably, J&J denied the allegations and filed a Motion to Dismiss the companies’ charges with the Federal Court. J&J claimed that the complaint should be dismissed because PharmaTech did not provide a “plausible” basis for the allegations of infringement. The Judge was not persuaded by their arguments and denied, without prejudice, the Motion to Dismiss from the bench during a hearing on March 13, 2017. The Federal Judge also identified a series of milestone dates that will optimally lead to a more rapid process and outcome.

Keith Berman, Principal Executive of Decision Diagnostics, stated, “Another hearing, another time the J&J Goliath loses. Our string of consecutive litigation victories against arguably the most powerful healthcare company on the planet now extends back for years and includes the recent ruling by the Supreme Court of the United States. Allegorically, DECN’s PharmaTech Solutions subsidiary has become the Harlem Globetrotters to J&Js Washington Generals. Five years ago, it would have been inconceivable for J&J to be reasonably compared to the most renowned loser throughout history. “

The court ruled that PharmaTech would be permitted to file an amended complaint in which it could provide further detail concerning its claim for infringement under the Doctrine of Equivalents. The court further instructed the parties to engage in limited discovery directed to the infringement issues and set a schedule for completion of fact and expert discovery, at the end of which the parties could file Motions for Summary Judgment.

Mr. Berman continued, “Our shareholders have derived personal satisfaction from repeatedly defeating the company, which has overtly and illicitly subverted our legitimate efforts to present a superior and inexpensive blood glucose test strip alternative to the suffering diabetic patient population. That personal satisfaction will, however, be transformed into financial appreciation. J&J was eviscerated in their prior attempts and their losing streak now continues with our legal pursuit of justice for their violation of our patent integrity with the clear infringement of the Decision Diagnostic subsidiary owned US patents 6,153,069 and 6,413, 411.”

The honorable Richard F. Boulware’s ruling in the Nevada Federal District Court was structured exactly as the company had hoped, but significantly more than had been reasonably expected. This result creates the desired landscape whereby the company patent attorneys and scientific experts can disseminate the indisputable arguments to extend its court victories and contribute the financial compensation that this overt violation of PharmaTech’s patent integrity warrants.

Forward-Looking Statements:

This release contains the Company’s forward-looking statements which are based on management’s current expectations and assumptions as of March 20, 2017, regarding the Company’s business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.

CONTACT INFORMATION

Decision Diagnostics Corp.
Keith Berman
(805) 446-2973

info@decisiondiagnostics.com
www.genultimate.com
www.decisiondiagnostics.com

SOURCE: Decision Diagnostics Corp.

ReleaseID: 457774

MIAMI, FL / ACCESSWIRE / March 21, 2017 / Bomberg watches and jewelry is proud to announce the newest addition to the Bomberg family: Latin Urban super star Nicky Jam has become the new friend of the Swiss watch & jewelry House. As mutual fans for one another, Bomberg is excited to be reemerging as one on this new endeavor.

Bomberg distinguishes itself by capturing demand as it happens, ready and willing to create exactly what the consumer desires. Nicky Jam had obstacles to overcome early on in his career but instead of giving up, he did what he had to do to distinguish himself from the rest. When things seemed to slow down for him in the USA, he decided to target his energy straight at his fans in Colombia and build up his fan base all over again. With persistence and tenacity, Nicky Jam was resurrected into a household name. The determination that Nicky Jam has shown is just the exact kind of heart and soul as well as values Bomberg is looking for in its partnerships and watches the brand creates.

Along with the partnership with Nicky Jam, the Swiss watch & jewelry House unveils two special edition pieces:

-The BOLT-68 Nicky Jam Quartz Chronograph: This timepiece comes in 45 mm diameter in black PVD and with a special black rubber strap. Its edition has been limited to 500 pieces world-wide. The chain & medallion are specific.

-The BOLT-68 Automatic 3 hands: A very limited edition of 100 watches world-wide. Besides the features of its quartz counterpart, this BOLT-68 Automatic 3-hands is available with a python strap.

Both time-pieces embellished with the “Fenix” the mythological bird that recycled its own life, igniting itself on fire only to reemerge from its ashes reborn, renewed, and very much alive – just as Nicky Jam.

BOMBERG IS MORE THAN A WATCH. IT’S A WAY OF LIFE

Bomberg Watches distinguishes itself by capturing demand as it happens, ready and willing to create exactly what the consumer desires.

BOMBERG is a newcomer to the World of Watches, first seeing the light of day in Neuchâtel, the cradle of the Swiss watchmaking industry, in 2012. But don’t let this fool you – the Brand has big ambitions and a clear message: BOMBERG is different.

ABOUT THE COLLECTIONS

Swiss made, strong, distinguished and unconventional, the collections reinterpret and completely overturn classic watchmaking rules to create unusual timepieces. The brand’s attention confirms its ability to reinvent the image in this industry. Through its quality and the particular attention given to every detail, the collections BOLT-68 and 1968 take the wristwatch to a new level opening up new horizons for its trend-setting wearer.

ABOUT BOMBERG

Creativity is the ability to think “outside the box” according to Rick De La Croix, Chairman of BOMBERG. His vision is to create and establish a longstanding watch brand with international exposure, creating a new, uncontested market space rather than competing in an existing one; a brand, which is not so much focusing on potential competitors, but rather concentrates on the needs and desires of its target community, capturing demand as it happens.

Media Contact:

Lucy Tallo
lucy@pr-ticular.com
+41 79 393 42 66
www.bomberg.ch

SOURCE: Bomberg

ReleaseID: 457832

NEW YORK, NY / ACCESSWIRE / March 21, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued a report on United Health Products, Inc. (OTCQB: UEEC).

The report is available here: UEEC Primer.

We initiate preliminary coverage of United Health Products, Inc. (OTCQB: UEEC, “United Health Products”). We see United Health Products as a speculative microcap investment option in healthcare sector targeting the multi-billion dollar hemostatic and sealant markets. United Health has developed a patented hemostatic gauze intended for the healthcare and wound care sectors. The company’s flagship product, Hemostyp®, is an all natural hemostatic agent derived from regenerated oxidized cellulose, which has been shown to quickly control bleeding from open wounds and body cavities. UEEC has recently filed an application with the FDA that, if approved, would expand the indications for Hemostyp® to include new opportunities including use in general surgery. The company also continues to work towards sales distribution advancements in the retail, veterinary, dental, and dialysis markets.

United Health Products is based in Henderson, NV, and is led by CEO Douglas Belpate, an executive with over 30 years of experience in the medical device and wound care sectors. This note is an initiation primer and hence we are not issuing a price target or forward estimates for United Health Products at this time. We expect to issue a full initiation piece during calendar 2017.

Highlights from the report include:

Hemostyp® an all-natural approach to wound care

UEEC’s flagship Hemostyp® Topical Hemostatic Dressing is an all natural hemostatic agent. Hemostyp® has been shown to produce hemostasis in less than 45 seconds when applied to an open wound. The product has received FDA approval as a Class 1 device designed to absorb exudate//drainage from superficial wounds and help control bleeding, and is sold in prescription and over-the-counter formulations. Initially the company has targeted the medical, sports, dental, military and veterinary sectors. Hemostyp® is a 100% cellulose product that is made through a patented process from regenerated cotton cellulose, and then oxidized and etherized to become water-soluble. When contacting blood and exudates, the Hemostyp® cellulose expands into clear gel, resulting in a process of adhering and creating pressure to seal the wound.

UEEC files for expanded use indications for flagship Hemostyp® products under 510(k) program for surgical setting

United Health Products has recently taken a significant stride forward on the regulatory front. The company is seeking to expand the indications for its flagship Hemostyp® regenerated cellulose product. The company filed for expanded use indications for Hemostyp® under its current 510(k) application with the FDA. Hemostyp® is already cleared as a Class 1 device, which is indicated for topical wound dressing for temporary control of external surface bleeding.

The amended application seeks to achieve Class 2 clearance, indicated for use for internal procedures for controlling and managing bleeding. If approved, the expanded indications would allow Hemostyp® expanded applications of use in surgical settings, significantly increasing the market potential for the company. In an announcement describing the amended 510(k) application, UEEC management stated that it expected a response from the FDA within 90-180 days.

UEEC targeting significant market opportunity with Hemostyp®

If approved, the expansion of indications for Hemostyp® would likely increase total available market for UEEC. Indeed, if the company is successful in its regulatory efforts, Hemostyp® would be cleared as a Class 2 device, which management believes would enable indications for general surgical procedures. UEEC believes that Hemostyp® will have initial applications in both the hemostatic and sealant markets, which were estimated to be $6.5bn globally in 2016. These are very attractive end markets, which are expected to grow at approximately 10% a year through 2017E, totaling $7.7bn.

Encouraging order activity in veterinary market

In January 2017, UEEC held a call with investors and stakeholders to update progress in new distribution channels, and reported encouraging order activity in the veterinary market. During the call, management stated that the company is progressing with its distribution agreement with Animal Health International, and that the company began its initial rollout for Patterson Veterinary and Animal Health International in December. In the call UEEC noted that combined Patterson Veterinary and Animal Health International are the largest veterinary product suppliers in the United States, with 85 distribution centers, which service more than 8,000 veterinary clinics around the country.

UEEC CEO, Douglas Beplate stated on the call that the company had agreed on an initial rollout of five SKUs with Patterson Veterinary and Animal Health International, which would initially cover 15 distribution centers. UEEC shipped 100,000 units to these distribution centers in December and management stated that another 200,000 units had been scheduled for March. Patterson has over 400 inside and outside sales representatives, who will be promoting Hemostyp® during calendar 1Q17, and UEEC is hopeful that initial results will warrant further penetration into the 85 center distribution network.

Please review important disclosures on our website at www.seethruequity.com.

About United Health Products Inc.

United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its products and increasing sales in its current markets. www.Unitedhealthproductsinc.com.

About SeeThruEquity

Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.

SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry’s most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 457831

NEW YORK, NY / ACCESSWIRE / March 21, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on FTE Networks Inc. (OTCQX: FTNW).

The report is available here: FTNW Update Note.

Based in Naples, FL, FTE Networks Inc. (OTCQX: FTNW, “FTE Networks”) is a provider of network infrastructure services and solutions. The company has nearly a decade of experience providing end to end network infrastructure solutions for Tier 1 and Tier 2 communications service providers, government agencies, OEMs, and network infrastructure providers. FTE Networks is focused on helping customers build smarter networks, which are more capable of handling the increasing complexity and bandwidth needs of services provided over wireless and wired data networks. FTE is led by a seasoned leadership team with deep experience at industry technology leaders such as Zayo, Level3, and Qwest, among others.

Investment Highlights

Transformative announcements to start 2017

FTE has made several significant corporate announcements in 1Q17, which have the potential to be very positive for the company. These include an application to list shares on the Nasdaq Capital Markets, and what appears to be a transformative announcement that it will acquire Benchmark Builders, Inc. (“Benchmark”) – a move that will expand service capabilities while adding marquee customers and more than doubling its three-year backlog.

Benchmark acquisition augments backlog, service capabilities

On March 9, 2017, FTE announced the acquisition of privately held Benchmark Builders, Inc. in a $75mn cash and stock transaction. Based in New York, Benchmark was founded in 2008 and provides construction management services in the Northeastern United States. Benchmark specializes in what the company describes as “technologically complex work” and large projects in the telecommunications, commercial real estate, industrial, broadcast, technology, infrastructure, healthcare, and education industries. We are enthused about the potential from this deal given the boost to backlog – Benchmark is expected to add $300mn to the combined company’s 3-year backlog – and an impressive customer list. Benchmark’s website lists Google, Cushman & Wakefield, Colliers, and Fox, among others, as representative customers. Pending financing, the deal is expected to close in calendar 2Q17.

Nasdaq CM application, new orders show progress

FTE has also shown progress in its core business, as the company looks to execute on management’s bullish topline guidance for 2017 of $55mn in revenues. In a March press release, the company reiterated that its 3-year organic pipeline was $170mn and that it received follow-on orders in a $10mn project in Midtown Manhattan, which would imply powerful annual growth versus the 2016 estimate of $16.4mn. Additionally, FTE has applied for a listing on the Nasdaq CM, which, if approved, would be a significant development for the company.

Raising target to $2.75 on deal announcement

We are increasing the price target for FTE Networks to $2.75 per share at this time. We see several possible catalysts ahead for the company, with results and guidance for 2017 upcoming, the pending acquisition of Benchmark, and the company’s February application to uplist to the Nasdaq Capital Market.

Please review important disclosures on our website at www.seethruequity.com.

About FTE Networks Inc.

FTE Networks is on the leading edge of network transformation helping communications service providers, government and enterprise customers evolve their networks to meet advancing technology requirements via network infrastructure, and edge computing solutions to quickly enhance service innovation and deliver new revenue streams. With a focus on smart design, open architectures, and consistent standards, along with expertise in building, operating, and maintaining networks, FTE solves complex network and system challenges that reduce costs and deployment time to accelerate delivery and optimize performance of network infrastructure. Operating five (5) industry segments; Data Center Infrastructure, Fiber Optics, Wireless Integration, Network Engineering, and Compute to the Edge, FTE Networks is headquartered in Naples, Florida, with offices throughout the United States and Europe. www.ftenet.com.

About Benchmark Builders, Inc.

Benchmark is a New York-based construction manager and general contractor serving a diverse and sophisticated client base in the telecommunications, commercial, industrial, broadcast, technology, infrastructure, healthcare, and education industries. The company delivers unique project solutions in the complex New York marketplace. It emphasizes the ability of its experienced staff to become an integral part of a client’s project team, responding to every client need and request. Benchmark excels at technologically complex work building broadcast studios and infrastructure, as well as large projects from $30 million to $100 million. Benchmark maintains its strong reputation by consistently delivering on the quality, budget, and schedule expectations of some of the industry’s most demanding clients.

About SeeThruEquity

Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.

SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry’s most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 457827

VANCOUVER, BC / ACCESSWIRE / March 21, 2017 / Power Americas Minerals Corp. (TSXV: PAM) (“Power Americas” or the “Company”) is pleased to announce that it has been cleared by the Financial Industry Regulatory Authority (FINRA) and will be quoted on the OTC Markets in the United States under the symbol PWMRF.

Power Americas’ management recognizes the significant potential of expansion into the United States equity markets and trading on the OTC markets will allow U.S. investors easier access to Power America’s shares. The trading of Power Americas shares on the OTC markets will give greater accessible to an even broader range of investors and is expected to assist with increasing the liquidity and convenience of trading the Company’s shares within the United States.

In conjunction with receiving FINRA approval, the Company is applying for full DTC (Depository Trust Company) eligibility, allowing for Power America shares to be more easily and economically transferred between brokerage accounts electronically within the United States. DTC is the largest securities depository in the world, providing clearing and settlement efficiencies for brokers, as well as various other services.

About Power Americas Mineral Corp

Power Americas Minerals Corp. is a Canadian-based junior mining exploration company focused on the procurement, exploration and development of cobalt, lithium, copper and other energy metals in North and South America. The Company’s shares are listed and posted for trading on the TSX Venture Exchange under the symbol “PAM” and on the Frankfurt Exchange under the symbol “VV0”.

On behalf of the Board of Directors:

“Jeffrey Cocks”

Jeffrey Cocks
President

For more information please contact:
Howard Milne V.P. Business Development
Tel: (604) 377-8994 Email: hdmcap@shaw.ca
Website: www.poweramericascorp.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

NOT FOR DISSEMINATION IN THE UNITED STATES

SOURCE: Power Americas Minerals Corp.

ReleaseID: 457830

LONDON, UK / ACCESSWIRE / March 21, 2017 / Active Wall St. announces the list of stocks for today’s research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Asset Management industry. Companies recently under review include Gluskin Sheff + Associates, 49 North Resources, The Westaim, and Lorne Park Capital Partners. Get all of our free research reports by signing up at:

http://www.activewallst.com/register/

On Monday, March 20, 2017, at the end of trading session, the Toronto Exchange Composite index ended the day at 15,442.32, 0.31% lower, with a total volume of 307,366,310 shares. The TSX Venture Composite Index, on the other hand, closed at 811.63, up 0.13%.

Additionally, the Financials index was slightly down by 0.51%, ending the session at 289.72.

Active Wall St. has initiated research reports on the following equities: Gluskin Sheff + Associates Inc. (TSX: GS), 49 North Resources Inc. (TSX-V: FNR), The Westaim Corporation (TSX-V: WED), and Lorne Park Capital Partners Inc. (TSX-V: LPC). Register with us now for your free membership and research reports at:

http://www.activewallst.com/register/

Gluskin Sheff + Associates Inc.

Toronto, Canada-based Gluskin Sheff + Associates Inc.’s stock edged 0.79% lower, to finish Monday’s session at $17.68 with a total volume of 32,006 shares traded. Over the last one month and the previous one year, Gluskin Sheff + Associates’ shares have advanced 4.37% in the past three months. The Company’s shares are trading above its 200-day moving average. Gluskin Sheff + Associates’ 50-day moving average of $18.52 is above its 200-day moving average of $17.13. Shares of the Company, which provides wealth management services, are trading at a PE ratio of 13.94. See our research report on GS.TO at:

http://www.activewallst.com/register/

49 North Resources Inc.

On Monday, shares in Saskatoon, Canada-based 49 North Resources Inc. recorded a trading volume of 700 shares. The stock ended the day flat at $0.09. 49 North Resources’ stock has gained 28.57% in the previous three months. Shares of the Company, which specializes in seed capital and early stage investments, are trading below its 50-day and 200-day moving averages. The stock’s 50-day moving average of $0.11 is above its 200-day moving average of $0.10. The Company’s shares are trading at PE ratio of 0.96. The complimentary research report on FNR.V at:

http://www.activewallst.com/register/

The Westaim Corp.

On Monday, shares in Toronto, Canada-based The Westaim Corp. ended the session flat at $2.73 with a total volume of 53,800 shares traded. Westaim’s shares advanced 1.11% in the past three months. Shares of the Company, which specializes in direct and indirect investments through acquisitions, joint ventures, secondary investments both direct and indirect, fund of fund investments, and other arrangements, are trading above its 200-day moving average. Furthermore, the stock’s 50-day moving average of $2.76 is greater than its 200-day moving average of $2.71. Register for free and access the latest research report on WED.V at:

http://www.activewallst.com/register/

Lorne Park Capital Partners Inc.

Oakville, Canada-based Lorne Park Capital Partners Inc.’s stock closed the day 12.50% higher at $0.45. The stock recorded a trading volume of 7,500 shares. Lorne Park Capital Partners’ shares have gained 7.14% in the last one month and 9.76% in the past three months. Furthermore, the stock has gained 18.42% in the previous one year. Shares of the Company, which together with its subsidiary, Bellwether Investment Management Inc., operates as an investment management and wealth advisory company, are trading above their 50-day and 200-day moving averages. Moreover, the stock’s 50-day moving average of $0.40 is greater than its 200-day moving average of $0.38. Get free access to your research report on LPC.V at:

http://www.activewallst.com/register/

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 457801

LONDON, UK / ACCESSWIRE / March 21, 2017 / Active Wall St. announces the list of stocks for today’s research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Oil & Gas – E&P industry. Companies recently under review include Bellatrix Exploration, Crescent Point Energy, TORC Oil & Gas, and RMP Energy. Get all of our free research reports by signing up at:

http://www.activewallst.com/register/

On Monday, March 20, 2017, the Toronto Exchange Composite Index was down 0.31%, finishing the day at 15,442.32.

The Energy Index was also in the red, closing the day at 197.90, down 0.47%.

Active Wall St. has initiated research reports on the following equities: Bellatrix Exploration Ltd. (TSX: BXE), Crescent Point Energy Corporation (TSX: CPG), TORC Oil & Gas Ltd. (TSX: TOG), and RMP Energy Inc. (TSX: RMP). Register with us now for your free membership and research reports at:

http://www.activewallst.com/register/

Bellatrix Exploration Ltd

Calgary, Canada-based Bellatrix Exploration Ltd’s stock fell 1.96%, to finish Monday’s session at $1.00 with a total volume of 382,353 shares traded. Shares of the Company, which engages in the acquisition, exploration, development, and production of oil and natural gas reserves in the provinces of Alberta, British Columbia, and Saskatchewan, are trading below its 50-day and 200-day moving averages. Bellatrix Exploration’s 200-day moving average of $1.14 is above its 50-day moving average of $1.05. See our research report on BXE.TO at:

http://www.activewallst.com/register/

Crescent Point Energy Corp.

On Monday, shares in Calgary, Canada headquartered Crescent Point Energy Corp. recorded a trading volume of 3.11 million shares, which was higher than their three months average volume of 2.70 million shares. The stock ended the day 0.21% lower at $14.28. Shares of the Company, which acquires, explores, develops, and produces light and medium oil and natural gas properties in Western Canada and the US, are trading below its 50-day and 200-day moving averages. The stock’s 200-day moving average of $16.58 is above its 50-day moving average of $14.92. The complimentary research report on CPG.TO at:

http://www.activewallst.com/register/

TORC Oil & Gas Ltd

On Monday, shares in Calgary, Canada headquartered TORC Oil & Gas Ltd ended the session 2.11% lower at $6.49 with a total volume of 1.29 million shares traded. Shares of the Company, which engages in the exploration and production of petroleum and natural gas in the Western Canadian Sedimentary Basin, are trading below its 50-day and 200-day moving averages. Further, the stock’s 200-day moving average of $7.73 is greater than its 50-day moving average of $7.17. Register for free and access the latest research report on TOG.TO at:

http://www.activewallst.com/register/

RMP Energy Inc.

Calgary, Canada headquartered RMP Energy Inc.’s stock closed the day flat at $0.72. The stock recorded a trading volume of 105,022 shares. Shares of the Company, which engages in the exploration, development, and production of crude oil, natural gas, and natural gas liquids primarily in the Western Canadian Sedimentary Basin in the province of Alberta, Canada, are trading below their 50-day and 200-day moving averages. Moreover, the stock’s 200-day moving average of $0.82 is greater than its 50-day moving average of $0.77. Get free access to your research report on RMP.TO at:

http://www.activewallst.com/register/

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 457803